Compare Crispr Therapeutics AG (CRSP) vs HP Inc (HPQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs HP Inc — how do they compare? Crispr Therapeutics AG trades at $50.34 (market cap $4.97B), while HP Inc trades at $23.46 (market cap $22.52B). The key difference: HP Inc is far larger — about 4.5× Crispr Therapeutics AG's market cap, and HP Inc pays a 4.87% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | HPQ | |
|---|---|---|
Market Cap | $4.97B | $22.52B |
Sector | Health | Technology |
52-Week High | $76.78 | $29.35 |
52-Week Low | $44.34 | $18.20 |
Enterprise Value | $3.32B | $29.69B |
Dividend Yield | — | 4.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
HPQ trades at $24.77, up 2.27% today, with a bullish technical outlook and strong earnings momentum, beating estimates for three consecutive quarters. The stock offers a 4.8% dividend yield and trades at attractive valuation multiples, including a P/E of 9.17 and P/S of 0.41. Recent partnerships with OpenAI and Ferrari highlight strategic moves to enhance AI capabilities and innovation in the PC market.
The outlook is positive due to undervaluation, dividend income, and AI-driven growth potential, but risks include PC market volatility, competitive pressures, and reliance on hardware sales. Analyst consensus is mixed with a hold rating, but technical indicators suggest near-term strength with support at $24 and resistance at $25-26.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →
